Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T16:03:42.591Z.
Calculation as of: 2026-10-06T16:03:42.591Z.
Quote observation: 2026-10-06T16:00:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6608cd76dc650ef8b2fc8232603ca313d9f3e0951a45c9e65e7ec74b346396eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Karyopharm Therapeutics Inc.
Market Cap
$15.07M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.25M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.30M
Free Cash Flow Yield
N/A
TTM Avg
1.23%
3Y Avg
1.23%
5Y Avg
1.23%
Market Cap
$14.51M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.44M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.75M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.05M
Free Cash Flow Yield
N/A
TTM Avg
3.99%
3Y Avg
3.12%
5Y Avg
3.97%
Market Cap
$13.97M
Free Cash Flow Yield
3.76%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$13.88M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.07M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.25M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | N/A | 1.23% | 1.23% | 1.23% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.51M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.05M | N/A | 3.99% | 3.12% | 3.97% |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 3.76% | 3.56% | 3.56% | 3.56% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.88M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
